52 related articles for article (PubMed ID: 11830535)
21. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL
Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155
[TBL] [Abstract][Full Text] [Related]
22. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
Anderson LD; Petropoulos D; Everse LA; Mullen CA
Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
[TBL] [Abstract][Full Text] [Related]
24. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
25. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
26. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
Teshima T; Liu C; Lowler KP; Dranoff G; Ferrara JL
Cancer Res; 2002 Feb; 62(3):796-800. PubMed ID: 11830535
[TBL] [Abstract][Full Text] [Related]
27. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
28. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
29. [Donor leukocyte infusion after allogeneic stem cell transplantation].
de Lacerda JF
Acta Med Port; 1999; 12(7-11):255-64. PubMed ID: 10707463
[TBL] [Abstract][Full Text] [Related]
30. Reimmunization after allogeneic bone marrow transplantation.
Somani J; Larson RA
Am J Med; 1995 Apr; 98(4):389-98. PubMed ID: 7709953
[TBL] [Abstract][Full Text] [Related]
31. The new genetics of bone marrow transplantation.
Allen RD
Genes Immun; 2000 Jun; 1(5):316-20. PubMed ID: 11196692
[TBL] [Abstract][Full Text] [Related]
32. Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation.
Mullen CA
Leuk Lymphoma; 2002 Mar; 43(3):503-10. PubMed ID: 12002752
[TBL] [Abstract][Full Text] [Related]
33. T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients.
Slobod KS; Benaim E; Woodruff L; Nooner S; Houston J; Holladay M; Lockey T; Hurwitz JL
Immunol Res; 2001; 24(3):289-301. PubMed ID: 11817326
[TBL] [Abstract][Full Text] [Related]
34. Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions.
Vandenberghe P; Boogaerts MA
Ann Hematol; 1995 Nov; 71(5):209-17. PubMed ID: 7492623
[No Abstract] [Full Text] [Related]
35. Immunomodulation after allogeneic bone marrow transplantation by CD4+CD25+ regulatory T cells.
Hoffmann P; Boeld TJ; Piseshka B; Edinger M
Microbes Infect; 2005 Jun; 7(7-8):1066-72. PubMed ID: 15951214
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?
Zöller M
Technol Cancer Res Treat; 2003 Jun; 2(3):237-60. PubMed ID: 12779354
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
